| |
ValueTrak is a real-time, cloud-based aggregation and analytics platform that transforms sales, inventory, and patient data into actionable insights. With speed and agility, its dashboards, scorecards, and customized reports provide deep insights. Learn more. 
|
|
| By Max Bayer,Gabrielle Masson More than 20 biotechs entered the biotech graveyard this year, spurred by a difficult financing environment. There were more than three times as many companies that closed or wound down in 2023 compared to 2022. |
|
|
|
By Fraiser Kansteiner After plunging COVID revenues prompted Pfizer to embark on a cost-cutting crusade, more details about the company's savings efforts are coming into focus. |
By Gabrielle Masson Pfizer’s new cost-saving agenda will see five pipeline programs in oncology, rare disease and immunology packed off to the graveyard. |
By Fraiser Kansteiner Sanofi acolytes are none too happy with the latest chapter of CEO Paul Hudson’s "Play to Win" strategy. After unveiling the pivot alongside third-quarter earnings Friday, Sanofi’s stock plunged nearly 20%, with one analyst group suggesting the plan came “at the wrong time.” |
|
Tuesday, November 7, 2023 | 10am ET / 7am PT Join us for a webinar to explore Advancements in Alzheimer's Disease Treatments, Expansive Opportunities in the Management of Diabetes and Obesity, and Groundbreaking Approaches to Treating Depression. Register now. 
|
|
By Max Bayer AbbVie CEO Rich Gonzalez says the company was aware of the potential for an ADC transaction with Daiichi that Merck ultimately pounced on, electing to prioritize internal work instead. |
By Annalee Armstrong A historic moment in pharmaceuticals will happen next week: an FDA advisory committee is set to review the first-ever CRISPR gene editing-based therapy, Vertex Pharmaceuticals and CRISPR Therapeutics’ exa-cel for sickle cell disease. |
By Angus Liu Aside from Pfizer's declining COVID-19 sales, GSK is giving the New York drugmaker another reason to worry. In the first round of their RSV vaccine showdown, GSK's Arexvy pulled down $860 million, more than doubling the haul from Pfizer's Abrysvo. |
By Conor Hale Though Philips has argued its U.S. subsidiary should be responsible for paying damages in its massive CPAP machine recall, instructions to continue selling home ventilators came from the parent company’s top leadership, according to ProPublica and the Pittsburgh Post-Gazette. |
By Helen Floersh The small molecule, which indirectly targets the tough-to-drug MYC gene, worked even better when combined with PARP 1/2 inhibitor talazoparib. |
By Nick Paul Taylor A group of pharmacy benefit managers has split off from the pack, launching a “six-figure digital media campaign” to make the case that some of the widely criticized organizations provide value to the healthcare system. |
By Kevin Dunleavy Aragen is earmarking $30 million for a factory in Bangalore to serve its “rapidly expanding” U.S.-based biologics business, the company said on Monday. It will be the third manufacturing facility in India for Aragen, a contract research development and manufacturing organization based in Hyderabad. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of “Podnosis,” we explore Blue Shield of California's plan to transform its pharmacy model. This includes a shift away from the traditional PBM relationship in favor of forming partnerships with five companies: Amazon Pharmacy, Abarca, Mark Cuban Cost Plus Drugs Company, CVS Caremark, and Prime Therapeutics. |
|
|---|
|
|
|
Thursday, November 9, 2023 | 11am ET / 8am PT Navigating the U.S. regulatory landscape for the use of high-purity alcohols in biologic development and manufacturing processes is crucial for maintaining product quality and patient safety. However, biomanufacturers often face significant challenges. Join us to gain key guidance from industry experts and learn important best practices. Register now. 
|
|
Whitepaper Is pharma spending money on the wrong types of AI? Here’s how real-time clinical alerts could change the minds of the world’s top commercial leaders. Sponsored by: Viz.Ai |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Want to know the Top 5 criteria for selecting the ‘right’ CDMO for pDNA manufacturing? Sponsored by: Syngene |
eBook Learn how to get better results from suboptimal biospecimens for NGS and protein analysis. Sponsored by: Covaris |
Whitepaper Learn more about targeted personas for HCP marketing. Sponsored by: M3 |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Accelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
Whitepaper Uncover the keys to efficient bioprocessing, including how outsourcing quality management can reduce risk, save time and money, and expedite biologics development. Sponsored by: Thermo Scientific™ Production Chemicals and Services |
Whitepaper Learn how to help patients with chronic diseases access tailored condition and treatment insights in an environment where they are often inundated with one-size-fits-all messaging that doesn’t align with their individual healthcare journey. Sponsored by: Phreesia Life Sciences |
Research Daiichi Sankyo wanted to create a “single source of truth, the very first place you should go” for content access and rights information. How did they replace five tools with just one? Sponsored by: CCC |
| Edison Ballroom, New York City |
|
|
| |
|
